<DOC>
	<DOC>NCT01686555</DOC>
	<brief_summary>To assess the safety, tolerability and pharmacokinetics of ABT-199 in female subjects with Systemic Lupus Erythematosus.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)</brief_title>
	<detailed_description>This is a phase 1, randomized, double-blind, placebo-controlled, single-and multiple ascending dose study. Up to eighty-eight subjects with Systemic Lupus Erythematosus will be selected to participate. Subjects will be randomized to receive either ABT-199 or placebo. Subjects will be administered ABT-199/placebo as a single dose or up to 14 days as multiple doses.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Diagnosis of systemic lupus erythematosus for at least 6 months. Documentation of at least one of the following: ANA titer &gt;= 1:160 or positive antidsDNA antibodies. Stable systemic lupus erythematosus medication regimen. Other than systemic lupus erythematosus, subject should be in general good health. Male. Druginduced or highly active systemic lupus erythematosus. Significant autoimmune disease other than lupus. Significant, uncontrolled or unstable disease in any organ.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>